CFTR and cystic fibrosis: In 2015, the combination (Orkambi®) of a corrector (Lumacaftor, VX-809) and a potentiator (Ivacaftor) was approved for ≥12-year-old patients with two copies of the p.Phe508del (c.1521_1523del) CFTR mutation (~44% of the CF population).